TP53 and melanoma: Our co-expression approach has been previously used to study multiple aspects of tumorigenesis in ERMS, T-cell acute lymphoblastic leukemia (T-ALL), melanoma, liver cancer, and neuroblastoma (Blackburn et al., 2014; Langenau et al., 2007; Lobbardi et al., 2017; White et al., 2013), and results in protein expression comparable to or lower than p53 in human Rh30 RMS cells that endogenously express mutant p53R273C (Gibson et al., 1998).